NCT04608838View on ClinicalTrials.gov

A Randomized Placebo-controlled Multicenter Trial to Evaluate the Efficacy and Safety of JTR-161, Allogeneic Human Dental Pulp Stem Cell, in Patients With Acute Ischemic stRoke (J-REPAIR)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

January 30, 2019

Primary Completion Date

February 15, 2021

Study Completion Date

November 24, 2021

Conditions
Acute Ischemic Stroke
Interventions
BIOLOGICAL

JTR-161

JTR-161 (1 or 3 × 10\^8 cells/subject) will be suspended and administered in an intravenously infusion.

BIOLOGICAL

Placebo

Placebo will be suspended and administered in an intravenously infusion.

Trial Locations (1)

113-8602

Nippon Medical School Hospital, Bunkyo-ku

All Listed Sponsors
lead

Teijin Pharma Limited

INDUSTRY

NCT04608838 - A Randomized Placebo-controlled Multicenter Trial to Evaluate the Efficacy and Safety of JTR-161, Allogeneic Human Dental Pulp Stem Cell, in Patients With Acute Ischemic stRoke (J-REPAIR) | Biotech Hunter | Biotech Hunter